BioHack Track models MK-677 (Ibutamoren) at a half-life of 24 hours, so every dose you log is decayed against that curve and the app shows estimated active levels — not just what you typed.
No approved product cited
No FDA-approved product for this compound is cited on this page, and no approved human dose is quoted. Treat the range below as research and community practice rather than a prescribed dose.
Reconstitution
Typically supplied as capsules or solution; no reconstitution needed.
Storage
Store at room temperature, away from light.
Cautions
Can increase appetite and water retention; monitor blood glucose with prolonged use.
Track MK-677 (Ibutamoren) in BioHack Track. Half-life, dose range and route come
pre-filled from this library — log a dose and the app counts your vial down, models what is
in your system, and puts it on the same chart as your labs and body composition.
Evidence Check asks 10 questions about every compound. For MK-677 (Ibutamoren) it can answer 4 of them, from the papers we hold — graded by how strong the study design is, not by whether the findings are flattering. These are the same verdicts the app gives.
Some Clinical EvidenceBone density
Clinical trials in humans have looked at this.
MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb studyRandomized Controlled Trial · Arch Gerontol Geriatr · 2011 · PMID 21067829
Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic womenRandomized Controlled Trial · J Clin Endocrinol Metab · 2001 · PMID 11238495
Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study GroupRandomized Controlled Trial · J Bone Miner Res · 1999 · PMID 10404019
Some Clinical EvidenceSleep
Clinical trials in humans have looked at this.
Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in manClinical Trial · Neuroendocrinology · 1997 · PMID 9349662
Some Clinical EvidenceWeight loss
Clinical trials in humans have looked at this.
Treatment of obese subjects with the oral growth hormone secretagogue MK-677 affects serum concentrations of several lipoproteins, but not lipoprotein(a)Randomized Controlled Trial · J Clin Endocrinol Metab · 1999 · PMID 10372705
Some Clinical EvidenceWound healing
Clinical trials in humans have looked at this.
Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study GroupRandomized Controlled Trial · J Bone Miner Res · 1999 · PMID 10404019
Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjectsRandomized Controlled Trial · J Clin Endocrinol Metab · 1996 · PMID 8954023
Research references only. Not medical advice, and not a recommendation to take anything.
Look up the research
These open a search of each database for MK-677 (Ibutamoren) — they are not citations, and nothing here is evidence for any particular dose. The same links are in the app.
10 papers naming MK-677 (Ibutamoren) in the title, drawn from PubMed and limited to reviews, meta-analyses and trials. Each was checked against PubMed’s own record for its title, journal and year. This is a starting point, not an evidence review — nothing here is offered as support for the dose range above, and the list is not exhaustive. See the editorial policy.
The half-life, route and dose range on this page are compiled from published
pharmacokinetic literature, manufacturer and product monographs where one exists, and the
ranges commonly reported in clinical and research use. They are kept as a range
rather than a single figure because that is what the sources actually support — a
half-life varies with route, formulation and the person.
These are not citations, and this page is not a review of the evidence. Where a
number matters to you, follow the database links above and read the source. We say so
plainly rather than dressing a compiled reference up as one.
Nothing on this page has been reviewed by a named clinician. It is a reference for
people already tracking a protocol, not a recommendation to start one.
Published by Creative Images LLC ·
Last updated ·
Corrections: support
General reference compiled for use
inside the app, not medical advice and not a recommendation to take anything. Dose ranges are
what is commonly discussed, not a prescription. Talk to a qualified healthcare professional.